Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 22,800 shares, a growth of 31.0% from the November 15th total of 17,400 shares. Approximately 1.4% of the company’s stock are short sold. Based on an average daily volume of 2,580,000 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a report on Wednesday, October 9th. They set a “sell” rating on the stock.

Galmed Pharmaceuticals Stock Performance

NASDAQ:GLMD traded up $0.16 on Friday, hitting $2.97. The stock had a trading volume of 31,667 shares, compared to its average volume of 714,124. Galmed Pharmaceuticals has a 1 year low of $2.56 and a 1 year high of $23.80. The firm’s fifty day simple moving average is $3.32 and its two-hundred day simple moving average is $3.96. The stock has a market cap of $1.90 million, a P/E ratio of -0.18 and a beta of 0.75.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.